Publications by authors named "Joshua A Ray"

Claim this Profile
C
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Ursula Becker, Andrew H Briggs, Santiago G Moreno, Joshua A Ray, Phuong Ngo

Value Health· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of innovation under value-based pricing.
Santiago G Moreno, Joshua A Ray

J Mark Access Health Policy· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.
Alain Vergnenègre, Joshua A Ray, Christos Chouaid, Francesco Grossi, Helge G Bischoff

Clinicoecon Outcomes Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
Joshua A Ray, Emma Carr, Gavin Lewis, Robert Marcus

Value Health· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.
Joshua A Ray, Rohit Borker, Beth Barber, William J Valentine, Vasily Belozeroff

Value Health· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of cinacalcet in addition to standard of care in the UK.
Joshua A Ray, William J Valentine, Andrew J Palmer

Nephrol Dial Transplant· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of diabetes case management for low-income populations.
Todd P Gilmer, Stéphane Roze, William J Valentine, Katrina Emy-Albrecht, Joshua A Ray

Health Serv Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Andrew J Palmer, William J Valentine, Joshua A Ray, Stephane Roze, Noemi Muszbek

Eur J Health Econ· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
Andrew J Palmer, William J Valentine, Joshua A Ray, Volker Foos, Francesco Lurati

Curr Med Res Opin· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Joshua A Ray, Kristina S Boye, Nicole Yurgin, William J Valentine, Stéphane Roze

Curr Med Res Opin· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Andrew J Palmer, William J Valentine, Daniel M D Tucker, Joshua A Ray, Stéphane Roze

Curr Med Res Opin· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
William J Valentine, Andrew J Palmer, Katrina M Erny-Albrecht, Joshua A Ray, David Cobden

Adv Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Andrew J Palmer, Stéphane Roze, William J Valentine, Joshua A Ray, Andreas Frei

Swiss Med Wkly· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Counting the costs of overweight and obesity: modeling clinical and cost outcomes.
Daniel M D Tucker, Andrew J Palmer, William J Valentine, Stéphane Roze, Joshua A Ray

Curr Med Res Opin· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin pumps: more consultation was needed.
Andrew J Palmer, Daniel M D Tucker, Joshua A Ray, William J Valentine, Craig Currie

BMJ· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Joshua A Ray, William J Valentine, Kristina Secnik, Alan K Oglesby, Anna Cordony

Curr Med Res Opin· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness studies of diabetes prevention in high-risk patients.
Andrew J Palmer, William J Valentine, Joshua A Ray

Expert Rev Pharmacoecon Outcomes Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis